title: Mitomycin-C induced hemolytic uremic syndrome: a case report.
abstract: Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome. We report a patient with a colonic adenocarcinoma who developed hemolytic uremic syndrome after receiving 85 mg/m2 of the drug. The patient was left untreated and died 5 months after this diagnosis was made, of a second malignancy. Differential diagnosis and treatment of this condition are discussed.
authors.affiliation: Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Rajaram K
authors.initials: RK
authors.lastname: Gundappa
authors.forename: Kamal
authors.initials: K
authors.lastname: Sud
authors.forename: Harbir S
authors.initials: HS
authors.lastname: Kohli
authors.forename: Krishan L
authors.initials: KL
authors.lastname: Gupta
authors.forename: Kusum
authors.initials: K
authors.lastname: Joshi
authors.forename: Vinay
authors.initials: V
authors.lastname: Sakhuja
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy; D000477:Alkylating Agents / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced / Q000175:diagnosis
chemical_list: D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D016685:Mitomycin